Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal

European Journal of Pharmacology

Volumn 530, Issue 1-2, 2006, Pages 95-102

  Göktalay, Gökhan ^a,b,c   Cavun, Sinan ^a,c   Levendusky, Mark C ^a   Hamilton, Jonathan R ^a   Millington, William R ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Ion Technologies Inc   (United States)

^c ULUDAG UNIVERSITY   (Turkey)

Author keywords

endorphin; Conditioned place preference; Dipeptide; Nicotine; Opioid; Pro opiomelanocortin

Indexed keywords

CYCLO(GLYCYLGLUTAMINE); GLUTAMINE DERIVATIVE; GLYCYLGLUTAMINE; KAPPA OPIATE RECEPTOR AGONIST; MECAMYLAMINE; NICOTINE; U50488; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSION; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG WITHDRAWAL; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMALS; AVOIDANCE LEARNING; CONDITIONING (PSYCHOLOGY); DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; MALE; MECAMYLAMINE; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PEPTIDES, CYCLIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 29844452534     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.11.034     Document Type: Article

References (58)

1. H. Akil, E. Young, S.J. Watson, and D.H. Coy Opiate binding properties of naturally occurring N- and C-terminus modified beta-endorphins Peptides 2 1981 289 292
2. R. Bals-Kubik, A. Herz, and T.S. Shippenberg β-Endorphin-(1-27) is a naturally occurring antagonist of the reinforcing effects of opioids N.S. Arch. Pharmacol. 338 1988 392 396
3. W.A. Banks, A.J. Kastin, V. Akerstrom, and J.B. Jaspan Radioactively iodinated cyclo(His-Pro) crosses the blood-brain barrier and reverses ethanol-induced narcosis Am. J. Physiol. Endocrinol. Metab. 264 1993 E723 E729
4. F. Berrendero, B.L. Kieffer, and R. Maldonado Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knock-out mice J. Neurosci. 22 2002 10935 10940
5. M.R. Caira, E. Buyukbingol, A. Adejare, and W.R. Millington Crystal structure of the dipeptide cyclo(glycyl-l-glutamine) Anal. Sci. 18 2002 1175 1176
6. D.J. Calcagnetti, and M.D. Schechter Reducing the time needed to conduct conditioned place preference testing Prog. Neuropsychopharmacol. Biol. Psychiatry 16 1992 969 976
7. D.J. Calcagnetti, and M.D. Schechter Nicotine place preference using the biased method of conditioning Prog. Neuropsychopharmacol. Biol. Psychiatry 18 1994 925 933
8. S. Cavun, G. Göktalay, and W.R. Millington Glycyl-glutamine, an endogenous β-endorphin-derived peptide, inhibits morphine conditioned place preference, tolerance, dependence and withdrawal J. Pharmacol. Exp. Ther. 315 2005 949 958
9. L.S. Covey, A.H. Glassman, and F. Stetner Naltrexone effects on short-term and long-term smoking cessation J. Addict. Dis. 18 1999 31 40
10. S. David, T. Lancaster, and L.F. Stead Opioid antagonists for smoking cessation Cochrane Database Syst. Rev. 2001 CD003086
11. S.L. Dewey, J.D. Brodie, M. Gerasimov, B. Horan, E.L. Gardner, and C.R. Ashby A pharmacologic strategy for the treatment of nicotine addiction Synapse 31 1999 76 86
12. R.M. Dores, M. Jain, and H. Akil Characterization of the forms of β-endorphin and α-MSH in the caudal medulla of the rat and guinea pig Brain Res. 377 1986 251 260
13. A.M. Epstein, and A.C. King Naltrexone attenuates acute cigarette smoking behavior Pharmacol. Biochem. Behav. 77 2004 29 37
14. M. Ezzati, and A.D. Lopez Estimates of global mortality attributable to smoking in 2000 Lancet 362 2003 847 852
15. P.J. Fudala, and E.T. Iwamoto Further studies on nicotine-induced conditioned place preference in the rat Pharmacol. Biochem. Behav. 25 1986 1041 1049
16. H.E. Gallo-Torres, E.P. Heimer, C. Witt, O.N. Miller, J. Meienhofer, and C.I. Cheeseman The in vivo gastrointestinal absorption in rats of the intact cyclo(l-leucylglycine) dipeptide Can. J. Physiol. Pharmacol. 62 1984 319 328
17. L. Haynes β-Endorphin C-terminal peptide evokes arachidonic acid release from cortical neurones Eur. J. Pharmacol. 192 1991 397 401
18. A. Herz Endogenous opioid systems and alcohol addiction Psychopharmacology 129 1997 99 111
19. S. Himmelseher, E. Pfenninger, and P. Herrmann Cerebrospinal and plasma amino acid concentrations after administration of i.v. glycyl-glutamine and glycyl-tyrosine containing amino acid solutions in humans JPEN J. Parenter. Enteral Nutr. 20 1996 281 286
20. M.D. Hirsch, and T.L. O'Donohue Structural modifications of pro-opiomelanocortin-derived peptides alter their behavioral effects markedly J. Pharmacol. Exp. Ther. 237 1986 378 385
21. J.R. Hughes, S.W. Gust, K. Skoog, R.M. Keenan, and J.W. Fenwick Symptoms of tobacco withdrawal. A replication and extension Arch. Gen. Psychiatry 48 1991 52 59
22. S. Krishnan-Sarin, B. Meandzija, and S. O'Malley Naltrexone and nicotine patch smoking cessation: a preliminary study Nicotine Tob. Res. 5 2003 851 857
23. C. Lerman, F. Patterson, and W. Berrettini Treating tobacco dependence: state of the science and new directions J. Clin. Oncol. 23 2005 311 323
24. Y.P. Loh Molecular mechanisms of β-endorphin biosynthesis Biochem. Pharmacol. 44 1992 843 849
25. D.H. Malin, J.R. Lake, P. Newlin-Maultsby, L.K. Roberts, J.G. Lanier, V.A. Carter, J.S. Cunningham, and O.B. Wilson Rodent model of nicotine abstinence syndrome Pharmacol. Biochem. Behav. 43 1992 779 784
26. D.H. Malin, J.R. Lake, V.A. Carter, J.S Cunningham, and O.B. Wilson Naloxone precipitates nicotine abstinence syndrome in the rat Psychopharmacology 112 1993 339 342
27. T. Mizuma, S. Masubuchi, and S. Awazu Intestinal absorption of stable cyclic dipeptides by the oligopeptide transporter in rat J. Pharm. Pharmacol. 50 1998 167 172
28. R.F. Mucha, and M.J.K. Walker Aversive property of opioid receptor blockade in drug-naive mice Psychopharmacology 93 1987 483 488
29. R. Nemeth-Coslett, and R.R. Griffiths Naloxone does not affect cigarette smoking. Naloxone does not affect cigarette smoking Psychopharmacology 89 1986 261 264
30. P. Nicolas, and C.H. Li β-Endorphin-(1-27) is a naturally occurring antagonist to etorphine-induced analgesia Proc. Natl. Acad. Sci. U. S. A. 82 1985 3178 3181
31. 30-31] attenuates hemorrhagic hypotension in conscious rats Am. J. Physiol. 273 1997 R1598 R1606
32. M.D. Owen, C.B. Unal, M.F. Callahan, K. Triveda, C. York, and W.R. Millington Glycyl-glutamine inhibits the respiratory depression, but not the antinociception, produced by morphine Am. J. Physiol. Regul., Integr. Comp. Physiol. 279 2000 1944 1948
33. D.C. Parish, D.G. Smyth, J.R. Normanton, and J.H. Wolstencroft Glycyl glutamine, an inhibitory neuropeptide derived from β-endorphin Nature 306 1983 267 270
34. C. Prasad Bioactive cyclic dipeptides Peptides 16 1995 151 164
35. M.L. Raffin-Sanson, Y. de Keyzer, and X. Bertagna Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions Eur. J. Endocrinol. 149 2003 79 90
36. G.E. Resch, S. Shridharani, W.R. Millington, D.R. Garris, and C.W. Simpson Glycyl-l-glutamine in nucleus accumbens reduces ethanol intake in alcohol preferring (P) rats Brain Res. Brain Res. 1058 2005 73 81
37. F.O. Risinger, and R.A. Oakes Nicotine-induced conditioned place preference and conditioned place aversion in mice Pharmacol. Biochem. Behav. 51 1995 457 461
38. M. Rukstalis, C. Jepson, A. Strasser, K.G. Lynch, K. Perkins, F. Patterson, and C. Lerman Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm Psychopharmacology 180 2005 41 48
39. S. Sakurada, T. Sakurada, H. Jin, T. Sato, K. Kisara, Y. Sasaki, and K. Suzuki Antinociceptive activities of synthetic dipeptides in mice J. Pharm. Pharmacol. 34 1982 750 751
40. C.W. Simpson, R.E. Resch, W.R. Millington, and R.D. Myers Glycyl-l-glutamine injected centrally suppresses alcohol drinking in P rats Alcohol 16 1998 101 107
41. P.D. Skoubis, H.W. Matthes, W.M. Walwyn, B.L. Kieffer, and N.T. Maidment Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice Neuroscience 106 2001 757 763
42. P.D. Skoubis, H.A. Lam, J. Shoblock, S. Narayanan, and N.T. Maidment Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice Eur. J. Neurosci. 21 2005 1379 1384
43. B.S. Slusher, A. Thomas, M. Paul, C.A. Schad, and C.R. Ashby Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated-α-linked- acidic dipeptidase (NAALADase) Synapse 41 2001 22 28
44. A.I. Smith, and J.W. Funder Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues Endocr. Rev. 9 1988 159 179
45. G. Sutherland, J.A. Stapleton, M.A. Russell, and C. Feyerabend Naltrexone, smoking behavior and cigarette withdrawal Psychopharmacology 120 1995 418 425
46. T. Suzuki, M. Funada, M. Narati, M. Misawa, and H. Nagase Morphine-induced place preference in the CXBK mouse: characteristics of mu opioid receptor subtypes Brain Res. 602 1993 45 52
47. T. Suzuki, Y. Ise, M. Tsuda, J. Maeda, and M. Misawa Mecamylamine- precipitated nicotine-withdrawal aversion in rats Eur. J. Pharmacol. 314 1996 281 284
48. K. Tamura, C.P. Lee, P.L. Smith, and R.T. Borchardt Effect of charge on oligopeptide transporter-mediated permeation of cyclic dipeptides across Caco-2 cell monolayers Pharm. Res. 13 1996 1752 1754
49. T.M. Tzschentke Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues Prog. Neurobiol. 56 1998 613 672
50. C.B. Unal, M.D. Owen, and W.R. Millington Inhibition of β-endorphin-induced cardiorespiratory depression by glycyl-l-glutamine, a dipeptide derived from β-endorphin processing J. Pharmacol. Exp. Ther. 271 1994 952 958
51. C.B. Unal, M.D. Owen, and W.R. Millington Cyclo(Gly-Gln) inhibits the cardiorespiratory depression produced by β-endorphin and morphine Brain Res. 747 1997 52 59
52. J.A. Vazquez, M. Raghunath, and S.A. Adibi Uptake and hydrolysis of glycylglutamine at the blood-brain barrier Metabolism 41 1992 121 124
53. J.R. Volpicelli, A.I. Alterman, M. Hayashida, and C.P. O'Brien Naltrexone in the treatment of alcohol dependence Arch. Gen. Psychiatry 49 1992 876 880
54. C.L. Walters, J.N. Cleck, Y.C. Kuo, and J.A. Blendy μ-Opioid receptor and CREB activation are required for nicotine reward Neuron 46 2005 933 943
55. S.S. Watkins, L. Stinus, G.F. Koob, and A. Markou Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediate effects J. Pharmacol. Exp. Ther. 292 2000 1053 1064
56. G.Y. Wong, T.D. Wolter, G.A. Croghan, I.T. Croghan, K.P. Offord, and R.D. Hurt A randomized trial of naltrexone for smoking cessation Addiction 94 1999 1227 1237
57. S. Zakarian, and D.G. Smyth Distribution of β-endorphin-related peptides in rat pituitary and brain Biochem. J. 202 1982 561 571
58. M.R. Zarrindast, N. Faraji, P. Rostami, H. Sahraei, and H. Ghoshouni Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice Eur. J. Pharmacol. 74 2003 363 369